Clinical trials: Early-Stage Cancer
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
PRISM Trial: Partial Breast Versus Whole Breast Radiation in Early Breast Cancer
Breast-conserving surgery followed by radiotherapy is a standard treatment for women with early-stage breast cancer. Whole breast irradiation (WBI) is the current standard approach, but partial breast irradiation (PBI), which…
- Trial name
- PRISM (NCT07811635)
- Testing
- Ultra-Hypofractionated Partial Breast Irradiation, Ultra-Hypofractionated Whole Breast Irradiation
- Where
- 3 sites in Pakistan, Saudi Arabia and 1 more
- Volunteers
- 100 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
This study, titled "Evaluation of the effect of regular physical exercise in women with breast cancer on adjuvant hormone therapy," is a research project designed to see how guided exercise can help women recovering from breast…
- Trial name
- NCT07893327
- Testing
- Supervised exercise program
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
Low-Risk, Early Stage Breast Cancer
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy.
- Trial name
- NCT07629206
- Testing
- Cryoablation
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- IceCure Medical Ltd.
Mesothelioma, Malignant Mesothelioma (MM)
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition…
- Conditions
- Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma
- Trial name
- NCT05960773
- Testing
- Decitabine/cedazuridine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Cancer Survivorship
Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU)
Women treated for early-stage breast cancer commonly experience ongoing treatment-related symptoms while receiving adjuvant endocrine therapy.
- Conditions
- Breast Cancer, Breast Cancer Survivorship, Cancer Survivorship, Endocrine Therapy
- Trial name
- LYSA2PIFU (NCT07840534)
- Testing
- Patient-Initiated Follow-Up and ePRO Symptom Management
- Where
- Ireland
- Volunteers
- 30 people
- Sponsor
- University College Cork
Invasive Breast Cancer Early Stages
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group.
- Trial name
- NCT03390894
- Where
- 73 sites in Spain
- Volunteers
- 8,000 people
- Sponsor
- Spanish Breast Cancer Research Group
HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias
Screening Women With Prior HPV for Anal Neoplasia
The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
- Conditions
- HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
- Trial name
- SWAN (NCT05217940)
- Testing
- Diagnostic tests for anal cancer screening
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lung Cancer, Adjuvant
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation…
- Conditions
- Lung Cancer, Adjuvant, Post-surgical, EGFR
- Trial name
- REZILIENT4 (NCT07128199)
- Testing
- TAS6417
- Where
- 253 sites in United States, Argentina and 22 more
- Volunteers
- 360 people
- Sponsor
- Taiho Oncology, Inc.
Early-Stage Non-Small Cell Lung Cancer
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
- Trial name
- NCT07871214
- Testing
- Pumitamig, Carboplatin, Cisplatin
- Where
- 50 sites in United States, Australia and 12 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Early-stage Breast Cancer, Estrogen-receptor-positive Breast Cancer
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer.
- Trial name
- KePreSt (NCT06150898)
- Testing
- Prospective data and sample collection, Ketorolac 10 Mg Oral Tablet, Pregabalin 75mg
- Where
- Belgium
- Volunteers
- 112 people
- Sponsor
- Jules Bordet Institute
Early-stage HER2+ Breast Cancer
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).
- Trial name
- Close2HER (NCT07527741)
- Where
- 10 sites in Serbia
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Aerobic Exercise, Early Stage Triple Negative Breast Cancer
Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC
To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.
- Trial name
- NCT07216495
- Testing
- Exercise
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Early-stage Upper Gastrointestinal Cancer, Stomach Cancer, Adenocarcinoma
Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
Gastric cancer is a common malignant tumour worldwide, and in China, the incidence and mortality rates of gastric cancer remain high.
- Conditions
- Early-stage Upper Gastrointestinal Cancer, Stomach Cancer, Adenocarcinoma, Laparoscopy-assisted Surgery, Endoscope
- Trial name
- NCT07708012
- Testing
- Combined double-scope surgery
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- wangdongsheng
Breast Cancer Survivor, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Collaborative Research: Multiscale Modeling and Intervention for Improving Long-Term Medication
The goal of this study is to learn about the impact of an integrated medication monitoring system in breast cancer survivors aged 21-70 who are prescribed endocrine therapy.
- Trial name
- NCT06865755
- Testing
- integrated medication monitoring (MM) system
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- San Diego State University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Early-Stage Breast Carcinoma
SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers
SOLIS is a prospective, single-arm, single-institution pilot trial evaluating single-fraction stereotactic radiotherapy (24 Gy to the planning target volume with a simultaneous integrated boost of 30 Gy to the clinical target…
- Conditions
- Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Trial name
- SOLIS (NCT07844759)
- Testing
- Stereotactic Radiation Therapy, Endocrine Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Renaissance Institute of Precision Oncology and Radiosurgery
Early-Stage Breast Cancer
1-Week Versus 3-Week PBI
This non-inferiority, phase 3 clinical trial evaluates the cosmetic non-inferiority of a one-week regimen (26 Gy/5 Fx) versus a three-week regimen (40 Gy/15 Fx) using intensity-modulated radiation therapy (IMRT) for partial…
- Trial name
- NCT07832279
- Testing
- 3-week PBI, 1-week PBI
- Where
- China
- Volunteers
- 818 people
- Sponsor
- Fudan University
Estrogen Receptor-positive, Early Stage Endometrial Cancer
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
This is a window of opportunity study designed to provide short duration exposure to camizestrant prior to planned curative intent surgery, with the anticipated benefit of demonstrating target engagement and suppression of ER…
- Trial name
- CARA (NCT07840443)
- Testing
- Camizestrant
- Where
- 6 sites in Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Early-stage Invasive Lobular Breast Carcinoma
AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma
Invasive lobular breast carcinoma (ILC), the second most common breast cancer type, represents approximately 15% of all breast cancer cases.
- Trial name
- NCT07842055
- Where
- Greece
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group